News tagged with drug manufacturers

Added benefit of lixisenatide is not proven

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together ...

Aug 02, 2013
popularity not rated yet | comments 0

China launches crackdown on drug industry

(AP)—China announced a crackdown Wednesday on misconduct in its drug market, stepping up pressure on the problem-prone industry while it pursues a bribery investigation of GlaxoSmithKline.

Jul 17, 2013
popularity not rated yet | comments 0

Chinese police say Glaxo employees bribed doctors

China's police ministry accused executives of pharmaceutical supplier GlaxoSmithKline on Thursday of conducting a large and long-running bribery campaign to persuade doctors to prescribe drugs.

Jul 11, 2013
popularity 5 / 5 (1) | comments 0

Added benefit of dapagliflozin is not proven

Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...

Jun 06, 2013
popularity not rated yet | comments 0

Added benefit of ingenol mebutate is not proven

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act ...

Jun 06, 2013
popularity not rated yet | comments 0

Aflibercept in AMD: No proof of added benefit

It is not proven that patients with wet age-related macular degeneration benefit from the new drug aflibercept, as the drug manufacturer did not present any suitable data for a comparison with the current standard therapy ...

Jun 05, 2013
popularity not rated yet | comments 0

Indian drugs group eyes $5 bn Swedish deal

Indian group Sun Pharmaceutical Industries is in talks to buy leading Swedish drugmaker Meda AB in what could result in a $5 billion takeover, the Wall Street Journal reported on Friday.

May 31, 2013
popularity not rated yet | comments 0

Renaissance in new drugs for rare diseases

Once famously described as "orphan diseases, too small to be noticed, too small to be funded" in the Hollywood drama Lorenzo's Oil, rare diseases are getting unprecedented attention today among drug manufacturers, ...

May 13, 2013
popularity not rated yet | comments 0